PRESS RELEASE September 27, 2017

Immune Pharmaceuticals Announces Positive Results from Ongoing Phase 2 Trial of Bertilimumab in Bullous Pemphigoid

Results from six subjects demonstrate a large and statistically significant reduction in bullous pemphigoid activity despite aggressive prednisone tapering, with no serious adverse events. September 27, 2017 08:00 AM Eastern Daylight Time ENGLEWOOD CLIFFS, N.J.–(BUSINESS WIRE)–Immune Pharmaceuticals, Inc. (NASDAQ:IMNP) a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases, today […]

Keep Reading

PRESS RELEASE August 29, 2017

Immune Pharmaceuticals Receives NASDAQ Letter

August 29, 2017 04:15 PM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (“Immune”) announced today that on August 23, 2017, the Company received written notice from the Listing Qualifications Department of The NASDAQ Stock Market LLC (“Nasdaq”) that the Company no longer complies with the minimum stockholders’ equity requirement under NASDAQ Listing […]

Keep Reading

PRESS RELEASE August 28, 2017

Immune Pharmaceuticals Provides R&D and Business Update and Summary of Recent Financial Highlights

August 28, 2017 08:00 AM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–Immune Pharmaceuticals Inc. (NASDAQ:IMNP) (“Immune” or the “Company”) provided the following R&D and business update and summary of recent financial highlights. R&D Update Immune continues to focus on the development of its two core assets: (1) bertilimumab, a first in class, monoclonal antibody in Phase […]

Keep Reading

PRESS RELEASE August 19, 2017

Immune Pharmaceuticals Receives NASDAQ Letter

August 29, 2017 04:15 PM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–Immune Pharmaceuticals Inc. (NASDAQ: IMNP) (“Immune”) announced today that on August 23, 2017, the Company received written notice from the Listing Qualifications Department of The NASDAQ Stock Market LLC (“Nasdaq”) that the Company no longer complies with the minimum stockholders’ equity requirement under NASDAQ Listing […]

Keep Reading

PRESS RELEASE August 14, 2017

Immune Pharmaceuticals Appoints Tony Fiorino, MD, PhD as Chief Medical Officer and Chief Operating Officer

August 14, 2017 08:00 AM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–Immune Pharmaceuticals (NASDAQ:IMNP) (the “Immune” or the “Company”) announced today that it has appointed Tony Fiorino, MD, PhD to the joint position of Chief Medical Officer and Chief Operating Officer. Dr. Fiorino will be responsible for all research and development and clinical and manufacturing activities […]

Keep Reading

PRESS RELEASE August 9, 2017

CYTOVIA Inc, IMMUNE Pharma’s Oncology Subsidiary, Announces Publication of Results Showing Anti-Metastatic Properties of Its Lead Drug Ceplene® and Filing of a New Worldwide Patent

Additional potential in cancer immunotherapy with Ceplene in combination with Interleukin-15 (IL-15) August 09, 2017 09:30 AM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–Cytovia, the oncology subsidiary of Immune Pharmaceuticals Inc. (NASDAQ:IMNP) (“Immune”), a clinical stage biopharmaceutical company, today announced the publication of results showing favorable effects of its lead immunotherapeutic compound Ceplene® (histamine dihydrochloride) in cancer. […]

Keep Reading

PRESS RELEASE August 7, 2017

CYTOVIA Inc., IMMUNE Pharma’s Oncology Subsidiary, Announces the Publication of New Results in the British Journal of Haematology and Filing of a World-wide Patent Protecting the Use of Ceplene® in Chronic Myeloid Leukemia (CML)

Strengthens Intellectual property portfolio and expands potential clinical use and market opportunity August 07, 2017 09:27 AM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–Cytovia, the oncology subsidiary of Immune Pharmaceuticals (NASDAQ:IMNP) (“Immune” or the “Company”), a clinical stage biopharmaceutical company, today announced the publication of new results supporting the benefits of its lead compound Ceplene® (histamine […]

Keep Reading

PRESS RELEASE August 4, 2017

Immune Pharmaceuticals, Inc. Issues Letter to Shareholders

August 04, 2017 10:16 AM Eastern Daylight Time ENGLEWOOD CLIFFS, N.J.–(BUSINESS WIRE)–Immune Pharmaceuticals Inc. (NASDAQ; IMNP) a clinical stage biopharmaceutical company specializing in the development of novel targeted therapeutic agents in the fields of immuno-inflammation, dermatology and immuno-oncology, issued the following Letter to Shareholders. Dear Immune Shareholder, Set out below are a review of our asset […]

Keep Reading

PRESS RELEASE July 19, 2017

Immune Pharmaceuticals Provides Update on Plan to Implement a Spin-off of Cytovia into a Separate Publicly Traded Oncology Company

Immune shareholders to receive additional pro rata shares in Cytovia July 19, 2017 09:32 AM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–Immune Pharmaceuticals (NASDAQ: IMNP) (“Immune”) today confirmed it is continuing to structure and pursue a spin-off of Cytovia, Inc. (“Cytovia”), its subsidiary dedicated to the development and commercialization of Oncology drugs and drug candidates, into […]

Keep Reading

PRESS RELEASE July 13, 2017

IMMUNE Pharmaceuticals’ Oncology Subsidiary, CYTOVIA, Announces the Filing of a World-Wide Patent Protecting the Use of Ceplene® in Acute Myeloid Leukemia (AML) and Other Hematological Cancers with Mutated NPM1

Favorable relapse-free and overall survival in AML patients with persistent leukemic cells July 13, 2017 07:30 AM Eastern Daylight Time NEW YORK–(BUSINESS WIRE)–Cytovia, Inc. (“Cytovia”) the oncology subsidiary of Immune Pharmaceuticals Inc. (NASDAQ:IMNP) (“Immune” or the “Company”), a clinical stage biopharmaceutical company, announced the filing of a patent protecting the use of Ceplene® (histamine dihydrochloride) […]

Keep Reading